¹⁸F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer's Disease Diagnosis.

ABSTRACT: An early, biomarker-based diagnosis of Alzheimer's Disease (AD) is crucial, especially with the emerging availability of novel therapeutic options. However, the role of ¹⁸F-FDG-PET and its relationship to other PET and CSF biomarkers remains unclear. Therefore, the aim of this study was the evaluation of the role of ¹⁸F-FDG-PET in AD diagnosis and its relationship to other commonly used fluid and PET biomarkers and their individual and multimodal accuracy in AD diagnosis. We included n = 157 AD patients, n = 603 MCI patients, and n = 380 cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) that underwent PET imaging with ¹⁸F-FDG or ¹⁸F-Florbetapir. Clinical and imaging data including pat

SUBMITTER: Bouter Y 

PROVIDER: S-EPMC12669464 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature